1832 Asset Management’s Bionano Genomics BNGO Stock Holding History

1832 Asset Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	-$3K	–	871
2022 Q1	$3K	Buy	+2	New	+$2.7K	﹤0.01%	906

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

1832 Asset Management's BNGO Position: Q2 2022 in Review

1832 Asset Management sold out of Bionano Genomics (BNGO) in Q2 2022, closing a stake of 2 shares — an estimated $3K sold.

1832 Asset Management first reported a position in BNGO in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 143 funds tracked by Wall St. Rank hold BNGO as of Q2 2022.

1832 Asset Management reported no remaining Bionano Genomics position as of Q2 2022 after selling out during the quarter.
1832 Asset Management sold 2 Bionano Genomics shares in Q2 2022, an estimated $3K.
1832 Asset Management first reported a position in Bionano Genomics in Q1 2022 and held it in 1 quarter.
1832 Asset Management's Bionano Genomics position peaked at $3K in Q1 2022.
143 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2022.

Based on 1832 Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.